Top advances of the year in autologous cellular therapy in melanoma and solid tumors
The year 2025 marked significant advances in autologous cellular therapy for melanoma and solid tumors, building on landmark regulatory approvals in 2024. Lifileucel, the first Food and Drug Administration‐approved tumor‐infiltrating lymphocyte (TIL) therapy for advanced melanoma, demonstrated durable efficacy in the 5...
Kimberly Loo, A. Betof
· Cancer · 0 citations